| Document |
Document Title |
|
WO/2020/063696A8 |
Provided are a preparation of a semicarbazide-sensitive amine oxidase inhibitor and the use thereof. In particular, dislosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof....
|
|
WO/2021/069705A1 |
Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl,...
|
|
WO/2021/069671A1 |
The present invention is related to compounds of formula (I) and compounds of formula (II) and pharmaceutical composition thereof, useful as agonists of the CB1 and / or CB2 receptor(s).
|
|
WO/2021/068898A1 |
The present invention pertains to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor, a preparation method therefor, and a use thereof. Specifically, a compound with a structure of formula (I) is provide...
|
|
WO/2021/070091A1 |
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formul...
|
|
WO/2021/067682A1 |
The present disclosure provides compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs there...
|
|
WO/2021/067805A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2021/066435A1 |
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device comprising the organic electric element. According to the present invention, an organic electri...
|
|
WO/2021/063346A1 |
A novel KRAS G12C inhibitor. A compound represented by formula (I) and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compound represented by formula (I) and a composition thereof may effectively ...
|
|
WO/2021/066397A1 |
The present specification relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2021/041539A3 |
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
|
|
WO/2021/061706A1 |
The disclosure is in part directed to crystalline forms of (R)- 1'-(3 -(3,4-dihydro- 1,5- naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-sp
iro[benzofuran-2,4'- piperidin]-3 -amine, its salt, and variants thereof.
|
|
WO/2021/060240A1 |
The present invention relates to a compound represented by the formula (I) or a salt thereof, and a herbicide containing at least one selected therefrom as an active ingredient. In the formula (I), R1 represents a substituted or unsubsti...
|
|
WO/2021/057910A1 |
Disclosed is a peptidylarginine deiminase inhibitor and a use thereof. In particular, the present invention relates to a compound of peptidylarginine deiminase PAD4 inhibitor represented by formula (I) and various subformulas, a pharmace...
|
|
WO/2021/058445A1 |
The invention provides new heterocyclic compounds which are monoacylglycerol lipase (MAGL) inhibitors having the general formula (I) wherein A, L1, X, m, n and R1 to R4 are as described herein, compositions including the compounds, proce...
|
|
WO/2021/059136A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2021/058024A1 |
Provided are a class of heterospirocyclic compound which act as a lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in the preparation of a drug for treating diseases associated with LSD1. The heterospirocyclic compounds ...
|
|
WO/2021/060865A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/055630A1 |
The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical...
|
|
WO/2021/055591A1 |
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, l...
|
|
WO/2021/055627A1 |
The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, ...
|
|
WO/2021/055376A1 |
The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.
|
|
WO/2021/052501A1 |
Provided are a heterocyclic amide compound of general formula (I), a pharmaceutically acceptable salt thereof and a preparation method therefor, and the use of the compound in the preparation of a drug for treating diseases related to th...
|
|
WO/2021/052402A1 |
An antitumor pharmaceutical camptothecin derivative and an antibody-drug conjugate thereof. By means of a series of molecular structure modifications, an optimal camptothecin antitumor drug is obtained, so as to be more suitable as a dru...
|
|
WO/2021/048200A1 |
The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and m...
|
|
WO/2021/047674A1 |
A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.
|
|
WO/2021/048342A1 |
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2021/049654A1 |
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), a first light emitting layer (51) and a second light emitting layer (52) that is arranged between the first light emitting laye...
|
|
WO/2021/047556A1 |
Provided are a nitrogen-containing heterocyclic compound, and a preparation method therefor, a pharmaceutical composition comprising same and the use thereof. Specifically, provided in the present invention is a compound as shown in form...
|
|
WO/2021/048567A1 |
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositio...
|
|
WO/2021/047555A1 |
Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...
|
|
WO/2021/043077A1 |
(I) The present invention relates to a substituted pyrazine compound used as an SHP2 phosphatase inhibitor. Specifically, the present invention relates to the compound of formula (I) or a pharmaceutically acceptable salt, an ester, a ste...
|
|
WO/2021/045470A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2021/046382A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...
|
|
WO/2020/061375A8 |
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram -negative bacteria. Furthermore, the subject compounds and compositions are...
|
|
WO/2021/043616A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as plant growth regulators and/or seed germination promoters.
|
|
WO/2021/039789A1 |
The present invention addresses the problem of developing a reagent and a compound having a long phosphorescence lifetime for imaging of a low-oxygen cell or tissue, or measurement or quantification of the oxygen concentration in the low...
|
|
WO/2021/041539A2 |
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
|
|
WO/2021/039968A1 |
The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, Y represents an optionally ...
|
|
WO/2021/039824A1 |
An RNA methyltransferase inhibitor containing at least one type of compound selected from the group consisting of sulfonamide-based compounds represented by general formula (1) and pyrazoline-based compounds represented by general formul...
|
|
WO/2021/033980A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2021/032938A1 |
The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 a...
|
|
WO/2021/034118A1 |
The present specification pertains to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2021/032935A1 |
The present invention provides compounds of formula (I) or (Ia): compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 ...
|
|
WO/2021/034081A1 |
The present invention relates to a novel compound having excellent electron transport ability, light-emitting ability, and thermal stability, and to an organic electroluminescent device comprising same in one or more organic material lay...
|
|
WO/2021/032170A1 |
A tetracyclic compound as a Cdc7 inhibitor. Specifically disclosed is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof. (I)
|
|
WO/2021/034017A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2021/029715A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2021/030537A1 |
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
|
|
WO/2021/028645A1 |
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein ac...
|
